74 related articles for article (PubMed ID: 16823497)
1. Molecule of the month. Vildagilptin.
Drug News Perspect; 2006 May; 19(4):228. PubMed ID: 16823497
[No Abstract] [Full Text] [Related]
2. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
[No Abstract] [Full Text] [Related]
3. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
He YL; Horowitz A; Watson CE; Foley JE; Sallas W; Ligueros-Saylan M
J Clin Pharmacol; 2007 Jan; 47(1):127-31. PubMed ID: 17192511
[No Abstract] [Full Text] [Related]
4. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
[No Abstract] [Full Text] [Related]
5. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
6. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
[TBL] [Abstract][Full Text] [Related]
7. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
8. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
10. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
11. Treatments and devices for future diabetes management.
Capaldi B
Nurs Times; 2005 May 3-9; 101(18):30-2. PubMed ID: 15892503
[TBL] [Abstract][Full Text] [Related]
12. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
13. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
14. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
17. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Ahrén B; Foley JE
Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
[TBL] [Abstract][Full Text] [Related]
18. Three new drugs for type 2 diabetes.
Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
20. Islet cell function is as interesting as insulin resistance for T2DM treatment options.
Göke B
Int J Clin Pract Suppl; 2008 Mar; (159):1. PubMed ID: 18269434
[No Abstract] [Full Text] [Related]
[Next] [New Search]